28341065|t|Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
28341065|a|This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.
28341065	20	23	CSF	T031	UMLS:C0007806
28341065	24	26	AD	T038	UMLS:C0002395
28341065	27	37	biomarkers	T201	UMLS:C0005516
28341065	45	55	diagnostic	T058	UMLS:C0430022
28341065	56	66	evaluation	T058	UMLS:C0220825
28341065	70	78	dementia	T038	UMLS:C0497327
28341065	84	91	article	T170	UMLS:C1706852
28341065	131	138	Grading	T170	UMLS:C0441800
28341065	159	169	Assessment	T058	UMLS:C0220825
28341065	188	205	Evaluation method	T062	UMLS:C2911685
28341065	215	235	clinical application	T058	UMLS:C4084924
28341065	239	258	cerebrospinal fluid	T031	UMLS:C0007806
28341065	260	263	CSF	T031	UMLS:C0007806
28341065	265	278	amyloid-β1-42	T103	UMLS:C0169424
28341065	280	283	tau	T103	UMLS:C0085401
28341065	289	303	phosphorylated	T103	UMLS:C1519061
28341065	304	307	tau	T103	UMLS:C0085401
28341065	315	325	diagnostic	T058	UMLS:C0430022
28341065	326	336	evaluation	T058	UMLS:C0220825
28341065	354	362	dementia	T038	UMLS:C0497327
28341065	422	435	working group	T098	UMLS:C1883562
28341065	533	552	Alzheimer's disease	T038	UMLS:C0002395
28341065	554	556	AD	T038	UMLS:C0002395
28341065	574	582	dementia	T038	UMLS:C0497327
28341065	611	618	decline	T038	UMLS:C0234985
28341065	655	680	interpretation of results	T058	UMLS:C3526596
28341065	686	699	working group	T098	UMLS:C1883562
28341065	761	764	CSF	T031	UMLS:C0007806
28341065	765	767	AD	T038	UMLS:C0002395
28341065	768	778	biomarkers	T201	UMLS:C0005516
28341065	798	806	clinical	T062	UMLS:C0008972
28341065	807	817	evaluation	T058	UMLS:C0220825
28341065	835	844	uncertain	T033	UMLS:C0087130
28341065	888	890	AD	T038	UMLS:C0002395
28341065	907	915	dementia	T038	UMLS:C0497327
28341065	958	967	uncertain	T033	UMLS:C0087130
28341065	976	979	CSF	T031	UMLS:C0007806
28341065	980	982	AD	T038	UMLS:C0002395
28341065	983	993	biomarkers	T201	UMLS:C0005516
28341065	1005	1023	imaging biomarkers	T201	UMLS:C0005516
28341065	1089	1092	CSF	T031	UMLS:C0007806
28341065	1093	1102	biomarker	T201	UMLS:C0005516